| Literature DB >> 35812681 |
Meng Liang1, Li-Dan Li2, Liang Li3, Shuo Li4.
Abstract
Advances in nanotechnology have opened new frontiers in the diagnosis and treatment of cancer. Nanoparticle-based technology improves the precision of tumor diagnosis when combined with imaging, as well as the accuracy of drug target delivery, with fewer side effects. Optimized nanosystems have demonstrated advantages in many fields, including enhanced specificity of detection, reduced toxicity of drugs, enhanced effect of contrast agents, and advanced diagnosis and therapy of gastrointestinal (GI) cancers. In this review, we summarize the current nanotechnologies in diagnosis and treatment of GI cancers. The development of nanotechnology will lead to personalized approaches for early diagnosis and treatment of GI cancers. ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.Entities:
Keywords: Diagnosis; Gastrointestinal cancer; Nanodevices; Nanoparticles; Therapeutics
Year: 2022 PMID: 35812681 PMCID: PMC9210884 DOI: 10.12998/wjcc.v10.i16.5146
Source DB: PubMed Journal: World J Clin Cases ISSN: 2307-8960 Impact factor: 1.534
Figure 1Physiological function in the gastrointestinal tract and representative nanodevices used in gastrointestinal cancers.
Summary of types of nanodevices and their properties
|
|
|
|
|
|
| Iron | Imaging: MRI contrast, lymph nodes; antigen/receptor ligand, magnetic targeting; multiple treatment opportunities | Simplicity; low cost; high reproducibility | Adverse events in clinical use: Hypotension, lumbar pain and paresthesia | [ |
| QDs | Passive and active targeting; imaging through tunable autofluorescence; multiple treatment opportunities | Excellent PLQY; high photostability and biocompatibility; extreme fast synthesis | Toxicity | [ |
| Carbon | Passive and active targeting; treatment: Therapeutic cargo delivery; imaging: Visible, infrared | Lightweight, chemically and thermally stable; high tensile strength and conductivity; high resolution and good penetration into the tissue | Adverse events in clinical use: Inflammation, fibrosis | [ |
| Gold | Imaging: MRI contrast, fluorescence, optical properties; multiple treatment opportunities | Adjusted optical properties; high biocompatibility | Adverse events in clinical use: Nephrotoxicity | [ |
| Polymers | Passive targeting; antigen/receptor ligand targeting; tumor microenvironment-dependent drug release | High thermal stability, biocompatibility; good biodegradability and controlled drug release ability Inhibition of bacterial growth | Toxicity | [ |
NP: Nanoparticle; MRI: Magnetic resonance imaging; QDs: Quantum dot; PLQY: Photoluminescent quantum yield.
Examples of nanodevices currently under investigation for gastrointestinal cancer
|
|
|
|
|
| SPION | Colorectal; liver; gastric | Lymph node staging, detection of small metastatic lymph nodes.; magnetic NP-based biosensors for detection of biomarkers; companion diagnostics, evaluate accumulation and predict treatment efficacy of nanomedical cancer therapy | [ |
| QDs | Colorectal; liver; gastric | Cancer targeting and imaging; NIR-QD for simultaneous visualization of SLNs; multicolor QD probes for diagnosis of malignant tumors | [ |
| Carbon nanotubes | Colorectal; liver | Detection of lymph nodes and node metastasis; tumor localization | [ |
| Gold NPs | Colorectal; liver; gastric; pancreatic; esophageal | Photothermal effect; hyperthermia and cellular destruction; X-ray and CT contrast agents; targeted drug delivery | [ |
| Dendrimers | Pancreatic; colorectal | Dual targeting imaging; targeted drugs delivery and gene therapy; boron neutron capture therapy. | [ |
| Nanoshell | Gastric | Contrast agents; targeted drugs delivery and gene therapy | [ |
| Polymers | Colorectal; gastric; pancreatic; esophageal | Controlled drug delivery systems | [ |
NIR-QD: Near infrared-quantum dot; SLN: Sentinel lymph node; NP: Nanoparticle; SPION: superparamagnetic iron oxide NP; CT: Computed tomography.
Figure 2Nanodevices in diagnosis and therapy of gastrointestinal oncology.